Transforming growth factor (TGF)-b is known to promote tumor invasion and metastasis. Although bone morphogenetic proteins (BMPs), members of the TGF-b family, are expressed in a variety of human carcinoma cell lines, their roles in tumor progression have not been fully clarified. In this study, we sought to determine the roles of BMPs in the progression of breast cancer bone metastasis using human breast cancer samples and a mouse xenograft model. Immunohistochemical analysis of samples from breast cancer patients as well as a mouse xenograft model of MDA-231-D, highly metastatic human breast cancer cells, revealed phospho-Smad2 and phospho-Smad1/5/8 staining in the nuclei of cancer cells in primary tumor and/ or bone metastasis. Using a functional in vivo bioluminescence imaging system, we showed that TGF-b-and BMPinduced transcriptional pathways are active in bone metastatic lesions in vivo. In addition, both TGF-b3 and BMP-2 promoted the motility and invasiveness of the MDA-231-D cells in vitro. Moreover, expression of dominant-negative receptors for TGF-b and/or BMPs in the MDA-231-D cells inhibited invasiveness in vitro and bone metastasis in the xenograft model. These results suggest that BMPs as well as TGF-b promote invasion and bone metastasis of breast cancer.
Introduction
Members of the transforming growth factor (TGF)-b family, including TGF-b, activin, nodal and bone morphogenetic proteins (BMPs), are multifunctional cytokines that regulate a wide range of cellular responses, including cell proliferation, differentiation, adhesion, migration and apoptosis (Feng and Derynck, 2005) . BMPs were originally identified as osteoinductive cytokines at extraskeletal sites in vivo (Wozney and Rosen, 1998) . Subsequently, BMPs have been shown to play important roles during development and in the regulation of various cellular processes, such as migration, proliferation, apoptosis and differentiation of many different cell types (Hogan, 1996; Reddi, 1998; ten Dijke et al., 2003; Miyazono et al., 2005) . Recent reports revealed that perturbations of the BMP signaling pathways result in several clinical disorders, including juvenile polyposis, pulmonary arterial hypertension, chondrodysplasia and hemochromatosis (Waite and Eng, 2003; Katagiri et al., 2008) .
Signaling mediated by the TGF-b family cytokines is transduced through two distinct serine-threonine kinase receptors; the type I and type II receptors (Heldin et al., 1997; Shi and Massague´, 2003) . Upon ligand binding, type II and type I receptors form heterotetrameric complexes, in which the type II receptors, containing constitutively active kinases, phosphorylate the type I receptors. Seven type I receptors referred to as activin receptor-like kinase (ALK) 1 through 7 have been identified in mammals. TGF-b and activin bind to ALK5 and ALK4, respectively, whereas BMPs bind to ALK1, ALK2, ALK3 and ALK6. Upon activation by type II receptors, type I receptors transmit intracellular signaling through the activation of various proteins, such as Smads-the central mediators of the TGF-b family signaling (Miyazawa et al., 2002) . Smads are subdivided into three subtypes: receptor-activated Smads (R-Smads), common-mediator Smad (Co-Smad) and inhibitory Smads (I-Smads). The R-Smads, Smad2 and Smad3, are activated by TGF-b/activin/nodal receptors, whereas Smad1, Smad5 and Smad8 are activated by BMP receptors. Smad4 is the Co-Smad shared by the TGF-b/activin/nodal and BMP signaling pathways. Among the three different classes of Smads, only R-Smads directly interact with activated type I receptors, which activate these proteins by phosphorylating a conserved SSXS motif at their C termini. R-Smads then form heteromeric complexes with Smad4, followed by nuclear translocation and regulation of gene transcription in collaboration with other transcription factors and transcription regulators. I-Smads, Smad6 and Smad7, inhibit the phosphorylation of R-Smads by competing with R-Smads for binding to phosphorylated type I receptors.
Transforming growth factor-b signaling has a dual role in the progression and metastasis of tumors (Derynck et al., 2001) . During early stages of carcinogenesis, TGF-b signaling suppresses tumor cell growth. At the advanced stages of carcinogenesis, however, TGF-b induces epithelial-mesenchymal transitions and enhances the motility and invasiveness of cancer cells, resulting in promotion of metastasis (Tang et al., 2003; Wakefield and Roberts, 2002) . For example, TGF-b signaling has been shown to promote both lung and bone metastasis of breast cancer in mouse models. Moreover, in the osteolytic bone metastases by breast cancer cells, TGF-b released from the bone matrix stimulates neighboring tumor cells to produce osteolytic cytokines, thereby establishing a vicious cycle.
Several lines of evidence have implicated BMP signaling in cancer. BMPs are expressed in a variety of human carcinoma cell lines (Hatakeyama et al., 1993; Kim et al., 2000; Langenfeld et al., 2003) , and mutations of the human ACVR2 gene, encoding ALK2, have been reported to be responsible for the development of juvenile polyposis in some patients (Howe et al., 2001; Haramis et al., 2004) . BMP signaling has also been shown to inhibit tumorigenesis of several tumor types, including brain tumors, basal cell carcinomas of the skin and gastric cancer (Piccirillo et al., 2006; Sneddon et al., 2006; Bleuming et al., 2007) . On the other hand, recent evidence has shown that BMPs promote the motility and invasiveness of various cancer cells, including colon cancer, melanoma and prostate cancer cells (Rothhammer et al., 2005; Yang et al., 2005; Bailey et al., 2007; Grijelmo et al., 2007) . Furthermore, overexpression of BMP antagonist noggin in tumor cells inhibited osteolytic bone metastasis of lung and prostate cancer in mouse models (Feeley et al., 2006a, b) . The expression levels of components of the BMP signaling pathways have also been shown to correlate with the degree of breast cancer malignancy (Helms et al., 2005) . These results suggest that BMPs promote the progression of cancer metastasis. The roles of BMP signaling during the progression of bone metastasis of breast cancer, however, have not been clarified.
To elucidate the roles of BMPs in bone metastasis of breast cancer cells, we sought to determine whether the Smad signaling pathway is activated in clinical breast cancer samples and whether there is molecular biological evidence for a role of BMPs as mediators of bone metastasis in a mouse model system.
Results
Smad pathways are activated in human primary breast cancers and bone metastasis Transforming growth factor-b signaling has been reported to play an important role during progression of breast cancer (Tang et al., 2003; Wakefield and Roberts, 2002) . To determine whether BMP/Smad pathway is also active in breast cancer, primary tumor tissues from breast cancer patients with bone metastases were subjected to immunohistochemistry with anti-phosphopeptide antibodies against phospho-Smad2 or phosphoSmad1/5/8. The specificities of the anti-phospho-Smad2 and anti-phospho-Smad1/5/8 antibodies were confirmed by immunohistochemical analysis of paraffin-embedded MDA-231-D human breast cancer cells pretreated with or without TGF-b3 or BMP-2 (Supplementary Figure  S1) . The majority of the tested samples showed nuclear phospho-Smad2 staining in the tumor cells, suggesting the presence of active TGF-b signaling in the human primary breast cancer cells (Figure 1a , and Supplementary Table S1 ). All of the samples analysed also showed nuclear phospho-Smad1/5/8 staining, suggesting that primary breast cancer cells that develop into bone metastases are responsive to BMPs ( Figure 1a , and Supplementary Table S1 ). Interestingly, noncancerous mammary epithelial cells showed weaker or no phosphoSmad2 and phospho-Smad1/5/8 staining ( Figure 1a , lower panels).
To determine whether the Smad pathways are active in bone metastasis, we performed immunohistochemistry with anti-phospho-Smad2 or anti-phospho-Smad1/ 5/8 antibodies and metastatic tissues from breast cancer patients. The majority of the tested samples showed intense nuclear phospho-Smad2 and phospho-Smad1/5/ 8 staining in tumor cells (Figure 1b , and Supplementary  Table S1 ).
We also performed immunohistochemical analysis of lymph node metastasis tissues from the same patients. Lymph node metastasis tissues showed weaker phospho-Smad2 and phospho-Smad1/5/8 staining than those observed in the bone metastasis tissues (Figure 1c ). These findings suggest that breast cancer cells that have metastasized to bone may be stimulated by TGF-b and BMPs derived from the bone tissues.
Functional imaging reveals Smad-dependent transcription in a bone metastasis model To study the roles of BMPs in bone metastasis of breast cancer cells, we used a highly bone metastatic clone of MDA-MB-231 human breast cancer cells, MDA-231-D (Ehata et al., 2007) . BMP-2 and TGF-b3 phosphorylated Smad1/5/8 and Smad2, respectively, in parental MDA-MB-231 cells as well as in MDA-231-D cells (data not shown). Since these cells develop into severe bone metastases when injected intracardially into nude mice, and the enhancement in bone metastatic activity is tissue specific, they provide a good model for organspecific metastasis. Real-time reverse transcription-PCR analysis using mRNA samples from bone metastasis tissues of mice injected with parental MDA-MB-231 and MDA-231-D cells revealed that several genes that are related to tumor invasion and bone metastasis including matrix metalloproteinase MMP1/2, parathyroid hormone-related peptide (PTHrP) and the chemokine receptor CXCR4 were upregulated in bone metastasis tissues of MDA-231-D xenograft model (Supplementary Figure S2) .
Immunohistochemical analysis of an established MDA-231-D bone metastasis revealed prominent nuclear phospho-Smad1/5/8 staining as well as phospho-Smad2 staining in tumor cells, indicating that BMP and TGF-b signaling was active in the tumor cells (Figure 2a) . We further confirmed the phosphorylation of Smad2 and Smad1/5/8 by immunoblot analysis using samples from osteolytic MDA-231-D bone metastases (Figure 2b) .
We then assessed the bone metastases for Smaddependent transcriptional activity using functional imaging and the mouse xenograft model. To simultaneously We injected the cells intracardially into nude mice, and whole-body Rluc and Fluc imaging was performed ( Figure 2d ). Rluc activity in established bone metastases correlated with the osteolytic lesions observed by X-ray radiography (Figures 2e and f). These lesions also contained Fluc activity that did not correlate with the Rluc activity, demonstrating that the tumor cells contained BMP-dependent transcriptional activity (Figures 2d and e) . Moreover, bioluminescence imaging suggests that the BMP pathway is activated earlier in the progression of metastasis than is the TGF-b pathway. These results revealed that TGF-b-and BMP-induced transcriptional pathways were active in breast cancer cells located in the bone microenvironment, and that these transcriptional activities and the progression of bone metastasis could be examined in the same mouse.
TGF-b3 and BMP-2 promote the motility and invasiveness of MDA-231-D cells Cell motility and invasion are known to play significant roles in the progression of bone metastasis. TGF-b has been reported to induce the motility and invasiveness of various cancer cell lines including MDA-MB-231 cells. We then assessed the effects of TGF-b and BMPs on proliferation, motility and invasiveness of MDA-231-D cells in vitro. As shown in Figure 3a , TGF-b3 and BMP-2 did not affect the growth of these cells (Figure 3a) . We next examined the effects of TGF-b3 and BMP-2 on motility and invasion of MDA-231-D cells in vitro. In a wound-closure assay, BMP-2 as well as TGF-b3 induced MDA-231-D cells to become motile (Figure 3b ). Similar results were obtained using TGF-b1 instead of TGF-b3 (Supplementary Figure S3) . BMP-2 and TGF-b3 also induced these cells to invade through type-I collagencoated culture inserts (Figure 3c ). Moreover, we have found that treatment with TGF-b3 and BMP-2 in combination produced an additive effect on the invasiveness of these cells (Figure 3d ).
Inhibition of TGF-b and BMP signaling by DN-TbRII and DN-ALK3
To examine the effects of blocking the TGF-b and BMP signaling pathways in breast cancer cells, we generated lentivirus vectors that expressed dominant-negative forms of TGF-b type II receptor and the ALK3 BMP type IA receptor (DN-TbRII and DN-ALK3). DNTbRII specifically inhibits TGF-b signaling, whereas DN-ALK3 specifically suppresses BMP signaling. were used as a control (MDA-D-GFP). We confirmed the inhibitory effects of these proteins using immunoblot analyses to examine the phosphorylation state of the R-Smad proteins. TGF-b-induced phosphorylation of Smad2 was specifically inhibited by the expression of DN-TbRII, whereas BMP-induced phosphorylation of Smad1/5/8 was specifically suppressed by the expression of DN-ALK3 (Figures 4a and b) . We further confirmed the inhibitory effects of these constructs by analysing the transcription of target genes. TGF-binduced transcription of plasminogen activator inhibitor (PAI)-1 and Smad7 mRNA was specifically suppressed by DN-TbRII, whereas BMP-induced transcription of Id1 and Smad7 mRNA was specifically inhibited by DN-ALK3 (Figure 4c) .
Production of PTHrP and interleukin-11 (IL-11) by TGF-b in breast tumor cells is known to mediate osteolytic bone metastasis (Yin et al. 1999; Kakonen et al. 2002; Kang et al. 2003) . DN-TbRII reduced the expression level of PTHrP in MDA-231-D cells, whereas DN-ALK3 did not affect it (data not shown). On the other hand, the expression level of IL-11 mRNA and protein were significantly lower in the MDA-D-DN-ALK3 cells than in the MDA-D-GFP cells (Figure 4d) , although stimulation by exogenous BMP-2 showed a marginal effect on the expression of IL-11 in these cells (Supplementary Figure S4) . These results suggest that endogenous BMP signaling significantly affects the basal expression of IL-11.
Transforming growth factor-b3-induced invasion was specifically inhibited by the expression of DN-TbRII, whereas BMP-2-induced invasion was suppressed by the expression of DN-ALK3 (Figure 4e (Figures 5a-c) . Radiographic analysis also revealed that mice inoculated with MDA-D-DN-ALK3 cells showed significantly smaller bone lesions. (Figures 5a and b) . In addition, DN-ALK3 also reduced the frequency of osteolytic bone metastasis, although the difference was not statistically significant ( Figure 5c ). The expression of both DN-TbRII and DN-ALK3 only produced a small additional effect (Figures  5a-c) . Furthermore, the survival of the mice inoculated with MDA-D-DN-TbRII cells or MDA-D-DN-ALK3 cells was significantly prolonged compared with mice injected with MDA-D-GFP cells (Figure 5d ). It is important to note that expression of the dominantnegative receptors did not affect cell growth in vitro (data not shown). These results suggest that BMPs as well as TGF-b promote metastasis of breast cancer in vivo, and inhibition of either TGF-b or BMP signaling efficiently prevents bone metastases.
Discussion
Bone morphogenetic proteins are expressed in various carcinoma cell lines of gastric, ovarian, prostate, pancreatic and breast origin (Hatakeyama et al., 1993; Kim et al., 2000; Langenfeld et al., 2003) . Studies using a variety of tumor systems revealed that BMP signaling produces a complex set of effects in cancer, in which they can be either protumorigenic or antitumorigenic. On the one hand, BMP signaling has been suggested to inhibit tumorigenesis (Howe et al., 2001; Haramis et al., 2004; Piccirillo et al., 2006; Sneddon et al., 2006; Bleuming et al., 2007) , whereas emerging evidence has shown that BMPs promote the invasiveness and metastasis of several types of cancers (Helms et al., 2005; Rothhammer et al., 2005; Yang et al., 2005; Bailey et al., 2007) . Although these reports showed the expression of components of BMP signaling cascades in tumor tissues or active BMP signaling in cancer cell lines, no evidence for active BMP signaling in tumor cells in bone metastasis tissues has been reported.
Smads are central mediators of TGF-b and BMP signaling that are activated by type I receptor kinases. Our results show the presence of receptor-phosphorylated Smad1/5/8 as well as phosphorylated Smad2 in bone metastasis samples from breast cancer patients and a mouse xenograft model, demonstrating that BMP and TGF-b signaling in breast cancer cells in bone metastasis is active. Since BMPs are abundant in bone matrix, and breast cancer cells in bone metastases showed more intense phospho-Smad1/5/8 staining than cancer cells in primary tumor or lymph node metastases, our results suggest that breast cancer cells that have metastasized to bone are stimulated by BMPs released from the bone tissues. Phospho-Smad1/5/8 was also detected in cancer cells in primary tumor tissues and lymph node metastasis tissues, suggesting that in addition to paracrine signaling from bone matrixderived BMPs, autocrine BMP signaling affects breast cancer cells.
Although phosphorylation of R-Smads and accumulation of phosphorylated Smads in the nucleus are typical indicators of TGF-b and BMP stimulation, it is known that transcriptional corepressors, including c-Ski and SnoN, are overexpressed in some cancer cells, in which they inhibit TGF-b and BMP signaling through interactions with Smad complexes (He et al., 2003; Fukuchi et al., 2004) . To study whether Smad-dependent transcriptional pathways were active in the bone metastasis, we used a functional imaging system using a xenograft model. Dual-color bioluminescence imaging is useful for monitoring two molecular events in the same living animal (Arwert et al., 2007) . Using this system, we showed that TGF-b and BMP induced the Smaddependent transcriptional pathways to become active in highly bone metastatic MDA-231-D human breast cancer cells that were growing as bone metastases. Our findings suggest that in addition to TGF-b/Smad pathway, BMP/ Smad pathway also plays prominent roles in the formation of breast cancer-derived bone metastases, although it is likely that Smad-independent TGF-b and BMP signaling also contribute to the progression of bone metastasis. Indeed, BMP induced invasiveness of MDA-231-D cells in vitro. Moreover, expression of DN-TbRII and DN-ALK3 inhibited osteolysis and prolonged the Because Smad4 mediates both TGF-b and BMP signaling, these reports and our results suggest that TGF-b and BMP exert significant effects on the progression of breast cancer bone metastasis through the Smad pathways. The importance of Smad transcription factors in the progression of breast cancer was further demonstrated in studies in which Smad7 and c-Ski, which also inhibit both the TGF-b and BMP signaling pathways, efficiently inhibited lung and liver metastasis of breast cancer cells (Azuma et al., 2005) . Overexpression of Smad7 has also been reported to inhibit bone metastasis of melanoma cells (Javelaud et al., 2007) . Several molecules including PTHrP and IL-11 have been shown to be involved in TGF-b-induced bone metastasis of breast cancer (Yin et al. 1999; Kakonen et al. 2002; Kang et al. 2003) . In this study, we found that DN-ALK3, but not DN-TbRII, reduced the expression of IL-11, whereas DN-TbRII, but not DN-ALK3, decreased the expression of PTHrP in MDA-231-D cells. These results suggested that DN-TbRII and DN-ALK3 suppress bone metastasis, through regulation of the expression of distinct bone metastasis-related genes.
In this study, we have demonstrated that blockade of BMP signaling in cancer cells prevented bone metastasis in a xenograft model using a highly bone metastatic breast cancer cell line. On the contrary, Buijs et al. (2007) recently reported that BMP-7 overexpression in breast cancer cells antagonizes paracrine TGF-b signaling and inhibits osteolytic bone metastasis in a model of metastasis. Several differences in the experimental conditions used in their report and this study may explain the discrepancies in the results. Although both studies used cells derived from the MDA-MB-231 cell line, these clones were generated as bone-seeking clones using different methods. In addition, the xenograft model used in their study was an intraosseous inoculation model, whereas ours was an intracardiac inoculation model. Moreover, overexpression of BMP-7 used by Buijs et al. may affect both the cancer cells and the surrounding stroma, whereas DN-ALK3 inhibits BMP signaling only in the cancer cells. Further elucidation of the effects of BMPs on different tumor cells and microenvironments will be needed, if BMPs are to be used for cancer therapy.
Our results strongly support a model in which BMP signaling plays a significant role in breast cancer bone metastasis. In addition to natural BMP antagonists, including noggin, Yu et al. (2008) have recently developed dorsomorphin, a novel small-molecule inhibitor for BMP type I receptor kinases. Although the effects of BMP signaling on the progression of breast cancer bone metastases appear to be context-dependent, inhibition of BMP signaling offers a new potential therapeutic strategy for the treatment of metastases of breast cancer.
Materials and methods

Plasmids
DNAs encoding a dominant-negative form of TGF-b type II receptor (TbRII) that lacked its cytoplasmic domain (DN- TbRII), or a dominant-negative form of ALK3 that lacked its cytoplasmic domain (DN-ALK3), were transferred into the RfA sites of the lentiviral expression vector pCSII-CMV-RfA (a gift from Dr H Miyoshi, RIKEN) by the LR recombination reaction (Invitrogen, Carlsbad, CA, USA). To construct a lentiviral vector containing the BMP-responsive reporter Fluc, cDNAs encoding BRE-Fluc were inserted into the multicloning site of the lentiviral vector construct CS-CDF-CG-PRE. The TGF-b-responsive 9 Â CAGA-Fluc reporter vector and control CMV-Rluc vector were described previously (Ehata et al., 2007) .
Cell cultures
A highly bone metastatic human breast cancer cell line, MDA-231-D, was derived from the parental MDA-MB-231 line as described previously (Ehata et al., 2007) . Parental MDA-MB-231 cells and MDA-231-D cells were maintained in Dulbecco's modified Eagle's medium with 10% fetal bovine serum, 100 U/ ml penicillin and 100 mg/ml streptomycin.
Viral production and infection into target cells
Production of lentivirus encoding GFP, DN-TbRII, DN-ALK3 or imaging proteins and infection of MDA-231-D cells were performed as previously described (Ehata et al., 2007) .
Tumor sample analysis Formalin-fixed, paraffin-embedded primary breast tumor tissues, bone metastasis tissues and lymph node metastasis tissues were obtained during therapeutic procedures performed as part of routine clinical management of patients with breast cancer at the Japanese Foundation for Cancer Research (JFCR). Hematoxylin and eosin-stained sections were examined for regions that contained tumor cells and stroma, which were then analysed as serial sections for phospho-Smad2 and phospho-Smad1/5/8. All studies were conducted using protocols approved by the JFCR Institutional Review Board.
Immunohistochemistry
Dissected bones were isolated, fixed in 10% buffered formalin, decalcified in 10% EDTA and embedded in paraffin wax. Sections were stained with phospho-Smad2 antibody (Cell Signaling, Beverly, MA, USA) or phospho-Smad1/5/8 antibody (Cell Signaling). Antigen retrieval was performed using 10 mM sodium citrate (pH 6.0) at 97 1C for 10 min followed by incubation with primary and secondary antibodies and detection using the DAB (3, 3 0 -diaminobenzidine tetrahydrochloride) Liquid System (DakoCytomation, Glostrup, Denmark).
Intracardiac injections
All animal procedures were performed in the animal experiment room at the JFCR, according to the guidelines proposed by the Science Council of Japan. Female BALB/c nu/nu mice (4 weeks old) were purchased from Charles River Japan (Kanagawa, Japan). Mice were maintained under specific pathogen-free conditions. Intracardiac injections of MDA-231-D cells were performed as described (Ehata et al., 2007) . A successful injection was characterized by the pumping of arterial blood into the syringe. Development of bone metastasis was monitored weekly using X-ray radiography for up to 6 weeks. In experiments to assess survival, mice were killed when they became moribund.
Immunoblotting Immunoblotting was performed as described previously (Ehata et al., 2007) . Tumor lysates were prepared using CelLyticTM MT mammalian tissue lysis/extraction reagent (Sigma, St Louis, MO, USA), according to the manufacturer's instructions. Anti-phospho-Smad2 antibody (Cell Signaling), anti-Smad2/3 antibody (BD Transduction Laboratories, Franklin Lakes, NJ, USA), anti-phospho-Smad1/5/8 antibody (Cell Signaling) and anti-Smad1 antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) were used in this study.
Bioluminescence imaging analysis
Whole-body optical imaging was performed using a C2741-35A photon-counting VIM camera (Hamamatsu Photonics, Shizuoka, Japan) mounted in an A4178-11 image box (Hamamatsu Photonics). For Fluc imaging, mice were anesthetized (50 mg/kg sodium pentobarbital) and injected through the tail vein with 125 mg/kg endotoxin-free luciferin (Promega, Madison, WI, USA) in phosphate-buffered saline. For Rluc imaging, mice were anesthetized and given intravenous injection of 6.7 mg/kg coelenterazine (Sigma) in phosphate buffer. Imaging was completed between 2 and 5 min after injection. After 3 min of integration time, the distribution of the photons was indicated by a pseudo-color overlay on the gray scale image. Conversion of the photogenesis into a video signal and quantification of the signals were controlled by Aquacosmos Ver. 2.5 software (Hamamatsu Photonics).
Radiographic analysis of bone metastasis
Mice were anesthetized, placed in a prone position on wrapped films (Fuji Industrial X-ray Film FR; Fuji Photo Film, Kanagawa, Japan), and exposed to X-ray irradiation at 23 kV for 90 s using a Soft X-ray SOFRON apparatus (Sofron, Tokyo, Japan). Films were developed using a Fuji Medical Film Processor (SEPROS SV; Fuji Photo Film) and inspected for visible bone lesions. Osteolytic areas were quantified using ImageJ software.
Cell proliferation assay MDA-231-D cells were seeded in duplicate at a density of 3 Â 10 5 cells per well in 24-well plates. On the following day, cells were treated with TGF-b3 (1 ng/ml) or BMP-2 (30 ng/ml) and cultured for 24, 48, 72 or 96 h. Cells were trypsinized and counted with a Coulter counter (Beckman Coulter, Fullerton, CA, USA).
Wound-closure assay MDA-231-D cells were seeded at a density of 7 Â 10 5 cells per well in 12-well plates. On the following day, a wound was created with a pipette tip in the center of the culture. The cells were then treated with or without TGF-b3 or BMP-2 in serumfree Dulbecco's modified Eagle's medium. Photographs were taken using phase-contrast microscopy immediately and 24 h after the incision was made. Cells that migrated to the scratched area were counted.
Invasion assay
Invasion assays were performed as described previously (Ehata et al., 2007) . Cells were seeded at a density of 1 Â 10 5 cells per well in duplicate in the upper chambers of type-I collagencoated (Nitta Gelatin, Osaka, Japan), 12-well culture inserts (8-mm pore size; Becton Dickinson Labware, Franklin Lakes, NJ, USA) in the presence or absence of TGF-b3 or BMP-2. Thirty-six hours later, cells that invaded through the collagencoated-inserts were counted. Mean values for three randomly selected fields were obtained for each well.
Real-time reverse transcription-PCR
Quantitative real-time reverse transcription-PCR was performed as described previously (Ehata et al., 2007) . All samples were run in duplicate for each experiment. The primers used are listed in supplementary Table S2 . Values were normalized by human hypoxanthine phosphoribosyltransferase 1.
ELISA analysis
The production and secretion of IL-11 by MDA-231-D cells were determined in 24 h-conditioned media using Quantikine Human IL-11 Immunoassay (R&D Systems, Minneapolis, MN, USA), according to the manufacturer's instructions.
Statistical analysis
Survival rates were determined using the log-rank test. Other statistical evaluations were carried out using analysis of variance followed by a Tukey-Kramer post hoc test for the examination of differences between groups. Two-tailed Student's t-tests were used to compare two groups.
Abbreviations TGF-b, transforming growth factor-b; BMP, bone morphogenetic protein.
